Perfil
Paresh Vyas is the founder of Yellowstone Biosciences Ltd., where he holds the title of Chief Scientific Officer & Director.
He is also currently working as a Director at The Company of Biologists Ltd.
Cargos activos de Paresh Vyas
| Empresas | Cargo | Inicio |
|---|---|---|
The Company of Biologists Ltd.
 The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
The Company of Biologists Ltd.
The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Commercial Services |
- Bolsa de valores
- Insiders
- Paresh Vyas
